Skip to main content
Premium Trial:

Request an Annual Quote

Freenome Raises $300M in Series D Financing

NEW YORK – Freenome said on Tuesday that it has closed a Series D funding totaling $300 million, supported by existing and new investors.

The new funds bring the company's total financing since its founding in 2014 to over $800 million and will help support the advancement of its blood-based colorectal cancer screening test, currently being validated in a prospective registrational study.

It will also help speed the expansion of the firm's multiomic platform to other cancer types, such as pancreatic cancer, Freenome said.

The round was led by Perceptive Advisors and RA Capital Management, who were joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, and Soleus Capital Management.

New investors included ArrowMark Partners, Byers Capital, Eventide Asset Management, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, and Suvretta Capital Management.